Brief: Jade Biosciences Announces First Participant Dosed In First-In-Human Phase 1 Clinical Trial Of Jade201
26/05/2026 21:09
BRIEF-Jade Biosciences Announces First Participant Dosed In First-In-Human Phase 1 Clinical Trial Of Jade201 May 26 (Reuters) - Jade Biosciences Inc JBIO.O:
JADE BIOSCIENCES ANNOUNCES FIRST PARTICIPANT DOSED IN FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL OF JADE201, A NOVEL HALF-LIFE EXTENDED AFUCOSYLATED ANTI-BAFF RECEPTOR MONOCLONAL ANTIBODY
JADE BIOSCIENCES INC - INTERIM PHASE 1 FIH DATA FOR JADE201 EXPECTED IN 2027
Source text: ID:nGNX1Bm8Cj
Further company coverage: JBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million